Globus hystericus: globus syndrome?

1988 ◽  
Vol 102 (3) ◽  
pp. 231-234 ◽  
Author(s):  
Heikki J. Puhakka ◽  
Pentti Kirveskari
Keyword(s):  
Placebo Group ◽  
Treatment Group ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Occlusal Adjustment ◽  
New Name ◽  
Effect Of Treatment ◽  
Radiological Examinations

In a double-blind study, 22 patients with typical globus symptoms were investigated by both otolaryngological and odontological methods. All the patients underwent thorough hematological, endoscopic and radiological examinations. They were randomly divided into a treatment group and a placebo group and underwent either simple occlusal adjust or mock adjustment, respectivity. The result of occlusal adjustment was assessed immediately after completion of treatment. The effect of treatment on globus symptoms was assessed 2 to 3 months later in a double-blind study. Binomial tests showed that there was a significant association between the success of occlusal adjustment and disappearance of the globus symptom. A new name for this disease is proposed: the globus syndrome.

scholarly journals The use of Arsenicum album 30c to complement conventional treatment of neonatal diarrhoea (‘scours’) in calves

1994 ◽  
Vol 83 (04) ◽  
pp. 202-204 ◽  
Author(s):  
A. Rafferty ◽  
S. Kayne
Keyword(s):  
Placebo Group ◽  
Conventional Treatment ◽  
Treatment Plan ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Neonatal Calf ◽  
Neonatal Diarrhoea

AbstractIn a pilot double blind study carried out in Scotland, the effect of supplementing a conventional treatment plan with homoeopathic Arsenicum album was studied. In the management of neonatal calf scour it appeared that more animals recovered after one day in the group that had received active medicine, than in the placebo group. These results are encouraging.

scholarly journals Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults

2016 ◽  
Vol 115 (12) ◽  
pp. 2106-2113 ◽  
Author(s):  
Stephanie R. Rainey-Smith ◽  
Belinda M. Brown ◽  
Hamid R. Sohrabi ◽  
Tejal Shah ◽  
Kathryn G. Goozee ◽  
...  
Keyword(s):  
Older Adults ◽  
Treatment Group ◽  
Repeated Measures ◽  
Community Dwelling ◽  
Blind Study ◽  
Double Blind Study ◽  
Cognitive Measures ◽  
Double Blind ◽  
Time Treatment ◽  
Community Dwelling Older Adults

AbstractCurcumin therapy in animals has produced positive cognitive and behavioural outcomes; results of human trials, however, have been inconsistent. In this study, we report the results of a 12-month, randomised, placebo-controlled, double-blind study that investigated the ability of a curcumin formulation to prevent cognitive decline in a population of community-dwelling older adults. Individuals (n 96) ingested either placebo or 1500 mg/d BiocurcumaxTM for 12 months. A battery of clinical and cognitive measures was administered at baseline and at the 6-month and 12-month follow-up assessments. A significant time×treatment group interaction was observed for the Montreal Cognitive Assessment (repeated-measures analysis; time×treatment; F=3·85, P<0·05). Subsequent analysis revealed that this association was driven by a decline in function of the placebo group at 6 months that was not observed in the curcumin treatment group. No differences were observed between the groups for all other clinical and cognitive measures. Our findings suggest that further longitudinal assessment is required to investigate changes in cognitive outcome measures, ideally in conjunction with biological markers of neurodegeneration.

Clinical Evaluation of Three-Day Treatment of Vaginal Mycosis with Clotrimazole Vaginal Tablets

1983 ◽  
Vol 11 (3) ◽  
pp. 179-185 ◽  
Author(s):  
Shigemitsu Mizuno ◽  
Nankun Cho
Keyword(s):  
Treatment Group ◽  
Effective Treatment ◽  
Clinical Evaluation ◽  
Clinical Assessment ◽  
Adverse Reactions ◽  
Therapy Group ◽  
Day Treatment ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind

A double-blind study was conducted comparing a 3-day (200 mg once a day for 3 consecutive days) treatment with a 6-day (100 mg once a day for 6 consecutive days) treatment of clotrimazole inpatients with vaginal mycoses. Two days after therapy, fungal eradication was achieved in 87·7% of the patients who received 3-day therapy and 89·1% of patients who received 6-day therapy. With regard to the clinical assessment, 2 days after therapy the symptoms had disappeared in 54·4%, improved in 42·1%, were unchanged in 1·8%, and aggravated in 1·8% of the 3-day therapy group. The corresponding values in the 6-day group were 63·6%, 34·5%, 1·8% and 0%. Reappearance of fungi was found 2 weeks after therapy in 15·6% of the 3-day treatment group and 8·7% of the 6-day treatment group. No adverse reactions were seen in either group which necessitated the discontinuation of therapy. There were no statistical differences between any of the above results and it is therefore concluded that 3-day clotrimazole therapy is an effective treatment for primary vaginal mycosis.

Oxatomide in the Treatment of Chronic Allergic Rhinitis

1982 ◽  
Vol 91 (2) ◽  
pp. 175-178 ◽  
Author(s):  
E. Vannieuwenhuyse ◽  
F. Degreef ◽  
W. De Proost ◽  
J. Callier
Keyword(s):  
Allergic Rhinitis ◽  
Placebo Group ◽  
Side Effects ◽  
Treatment Period ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Therapeutic Control

Fifty-six patients with chronic allergic rhinitis were selected for a randomized double-blind study comparing oxatomide with a placebo. At the end of the 1-month treatment period symptoms had disappeared or were markedly improved in 81% of the oxatomide-treated patients compared with only 17% of the placebo group. Therapeutic control was achieved in most patients with a dose of 30 mg bid. Improvements were characterized by a reduction in the number, duration and severity of episodes of rhinitis. Oxatomide also significantly reduced the requirements of patients for additional antiallergic medication. No significant side effects were reported.

Effect of occlusal adjustment on mandibular dysfunction A double-blind study

1986 ◽  
Vol 44 (2) ◽  
pp. 63-69 ◽  
Author(s):  
Heli Forssell ◽  
Pentti Kirveskari ◽  
Pentti Kangasniemi
Keyword(s):  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Occlusal Adjustment

Changes in Headache After Treatment of Mandibular Dysfunction

Cephalalgia ◽  
1985 ◽  
Vol 5 (4) ◽  
pp. 229-236 ◽  
Author(s):  
Heli Forssell ◽  
Pentti Kirveskari ◽  
Pentti Kangasniemi
Keyword(s):  
Placebo Group ◽  
Muscle Contraction ◽  
Clinical Signs ◽  
Dental Occlusion ◽  
Headache Frequency ◽  
Double Blind Trial ◽  
Double Blind ◽  
Occlusal Adjustment ◽  
Effect Of Treatment ◽  
The Difference

To analyse the effect of treatment of mandibular dysfunction on headache, 35 patients with migraine, 20 patients with combination headache and 36 patients with muscle contraction headache were studied in a clinical double-blind trial. Patients in the treatment group received occlusal adjustment and those in the placebo group mock occlusal adjustment. After eight months and four months, respectively, the neurologist evaluated the treatment outcome. The frequency of headache was reduced in 79% and the intensity in 53% of patients suffering from muscle contraction headache or combination headache in whom the adjustment of the dental occlusion had been successfully accomplished. The difference from the placebo group was statistically significant. The decrease in headache frequency as calculated from the headache diaries correlated with the decrease in the index of clinical signs of mandibular dysfunction.

Placebo-Controlled Double-Blind Study Examining the Effectiveness of an Hypericum Preparation in 105 Mildly Depressed Patients

1994 ◽  
Vol 7 (1_suppl) ◽  
pp. 9-11 ◽  
Author(s):  
H. Sommer ◽  
G. Harrer
Keyword(s):  
Placebo Group ◽  
Depression Scale ◽  
Blind Study ◽  
Active Group ◽  
Double Blind Study ◽  
Hamilton Depression Scale ◽  
Double Blind ◽  
Group 13 ◽  
The Difference ◽  
Hypericum Extract

One hundred and five outpatients with mild depressions of short duration were treated in a double-blind study with either 3 x 300 mg hypericum extract or placebo. The therapy phase was 4 weeks. The effectiveness was judged according to the Hamilton Depression Scale after 2 and 4 weeks. The values of the mean basic score in these periods fell from 15.8 to 9.6 or 7.2 in the active group, and in the placebo group, from 15.8 to 12.3 and 11.3. The difference between active and placebo groups were statistically significant with P < .05 and P < .01 achieved after 2 and 4 weeks, respectively. In the active group, 28 of 42 patients (67%) and, in the placebo group, 13 of 47 Patients (28%) responded to treatment. Notable side effects were not found.

An experimental double-blind study to evaluate the use of Euphrasia in preventing conjunctivitis

1992 ◽  
Vol 81 (01) ◽  
pp. 22-24 ◽  
Author(s):  
Rupa Mokkapatti
Keyword(s):  
Placebo Group ◽  
Signs And Symptoms ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind

AbstractA double-blind study using Euphrasia 30c or placebo was carried out during an epidemic of viral conjunctivitis. Nine hundred and ninety-four subjects were available at follow-up, when 48 subjects in the group given Euphrasia and 43 subjects in the placebo group had signs and symptoms of conjunctivitis, a difference which was not statistically significant. The protocol by which Euphrasia was tried may be used without change to scientifically confirm the efficacy of a genus epidemicus. The concept of genus epidemicus lends itself well to experimental double-blind studies in homœopathy during epidemics.

Hypericum Treatment of Mild Depressions with Somatic Symptoms

1994 ◽  
Vol 7 (1_suppl) ◽  
pp. 12-14 ◽  
Author(s):  
W.-D. Hübner ◽  
S. Lande ◽  
H. Podzuweit
Keyword(s):  
Treatment Group ◽  
Side Effects ◽  
Active Treatment ◽  
Somatic Symptoms ◽  
Active Treatment Group ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Disturbed Sleep ◽  
Hypericum Extract

In a randomized, placebo-controlled, double-blind study, 39 patients with depression with somatic symptoms were treated with hypericum extract LI 160. The therapy lasted for 4 weeks; the dosage was 300 mg three times daily. At the onset of the study as well as after 2 and 4 weeks, the following criteria were analyzed: HAMD, B-L, CGI, and vegetative symptoms. The results show a significant improvement in the active treatment group at the 5% level as compared to placebo. Seventy percent of the patients treated with LI 160 were free of symptoms after 4 weeks. Typical symptoms of the depression such as lack of activity, tiredness, fatigue, and disturbed sleep, were especially responsive. In no case were any undesirable side effects observed.

Sign in / Sign up

Export Citation Format

Share Document